Mode
Text Size
Log in / Sign up

4% articaine improves anaesthetic success rates compared to 2% lidocaine in children with MIHKids' tooth pain: stronger numbing drug works better

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider 4% articaine over 2% lidocaine for improved anesthetic success in children with molar-incisor hypomineralisation.

This meta-analysis evaluates the efficacy of pharmacological, desensitizing, and behavioral strategies for managing pain and anxiety in children and adolescents with molar-incisor hypomineralisation (MIH). The study specifically compares 4% articaine against 2% lidocaine as a primary anesthetic agent.

Key findings indicate that 4% articaine achieved a pooled success rate of 0.849 for inferior alveolar nerve blocks and a pooled success rate of 0.915 for intraosseous injections, both of which were improved compared with 2% lidocaine. Additionally, the inclusion of pre-emptive ibuprofen, laser desensitization, and virtual reality distraction showed benefits for reducing pain and anxiety in this population.

The authors note that while 4% articaine showed improved success over 2% lidocaine, the evidence is not yet definitive. They state that further high-quality comparative studies are needed to establish specific clinical protocols. An individualized, multimodal approach may improve pain management for these patients, but clinical application should be tempered by the current need for more robust comparative data.

How this fits prior evidence

This meta-analysis addresses a gap in managing dental pain for children with molar-incisor hypomineralisation (MIH). While previous coverage noted that ibuprofen shows significant pain freedom for pediatric migraine treatment and that lidocaine cream with the Valsalva maneuver may reduce needle puncture pain, this study specifically addresses anesthetic success rates in MIH patients. It confirms that 4% articaine provides higher success rates than 2% lidocaine for both nerve blocks and intraosseous injections.

If your child has those chalky, sensitive molars, you know how tough dental visits can be. A condition called molar-incisor hypomineralisation (MIH) makes teeth weak and painful, and numbing them for treatment often fails. That means tears, anxiety, and sometimes a procedure that can't be finished.

A new analysis of existing studies looked at ways to improve pain control for kids with MIH. The big finding: a stronger local anesthetic, 4% articaine, worked better than the standard 2% lidocaine. When injected near the lower jaw nerve, articaine succeeded in about 85% of cases. When given directly into the bone, it succeeded about 92% of the time.

The analysis also found that giving ibuprofen before the procedure, using laser desensitisation, and using virtual reality distraction all helped reduce pain and anxiety. These strategies can be used alone or combined, depending on the child's needs.

It's important to note that this was a meta-analysis, meaning it combined results from several studies. The researchers say we still need more high-quality studies to confirm the best approaches and to guide dentists in everyday practice. But for parents and dentists, this points to a more personalized plan: a stronger numbing agent, plus other comfort measures, could make dental care much easier for kids with MIH.

What this means for you:
For kids with MIH, 4% articaine numbs better than 2% lidocaine, and adding ibuprofen, laser, or VR can ease pain and anxiety.

Common questions

What is molar-incisor hypomineralisation (MIH)?

MIH is a condition that affects children's molars and sometimes incisors. The enamel is weak and chalky, making teeth sensitive and prone to pain. Dental treatments on these teeth can be difficult because standard numbing may not work well.

What other strategies can help reduce pain and anxiety during dental treatment?

The analysis found that giving ibuprofen before the procedure, using laser desensitisation, and using virtual reality distraction all helped reduce pain and anxiety in children with MIH. These can be used along with a stronger anesthetic to make the experience more comfortable.

Is 4% articaine safe for children?

The analysis did not report on side effects or safety issues. It only looked at how well the numbing worked. Always talk to your child's dentist or doctor about the best and safest options for your child.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedSep 2026
View Original Abstract ↓
BACKGROUND: Pain management in children with molar-incisor hypomineralisation (MIH) presents a significant challenge, as affected teeth often respond poorly to local anaesthesia due to altered enamel and heightened pulp sensitivity. Overcoming these difficulties is crucial to achieving effective dental outcomes. AIM: To evaluate the effectiveness of pharmacological, desensitising and behavioural strategies for pain control in children and adolescents with MIH. DESIGN: Systematic search of multiple electronic databases identified studies published between 2001 and 2024. Eligible designs included randomised controlled trials, randomised crossover studies and clinical trials. Risk of bias was assessed using Cochrane RoB 2 and ROBINS-I V2 tools and certainty of evidence graded with GRADEpro. A random-effects meta-analysis was conducted to assess anaesthetic success with 4% articaine. RESULTS: Thirteen studies were selected, with six included in the meta-analysis. Pooled success rates for 4% articaine were 0.849 for inferior alveolar nerve block and 0.915 for intraosseous injection. Findings suggest improved anaesthetic success compared with 2% lidocaine. Pre-emptive ibuprofen, laser desensitisation and virtual reality distraction also showed benefits for reducing pain and anxiety. CONCLUSION: Current evidence suggests that an individualised, multimodal approach may improve pain management in children with MIH. However, further high-quality comparative studies are needed to guide clinical protocols. TRIAL REGISTRATION: PROSPERO Registration: CRD42024474840.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.